Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AVR118: Phase I/II data

Preliminary results from an open-label, dose-escalating, Israeli Phase

Read the full 81 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE